Functional Bladder Problems

Slides:



Advertisements
Similar presentations
International Neurourology Journal 2012;16:41-46
Advertisements

Pascal Rischmann  European Urology Supplements 
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Urinary Nerve Growth Factor Levels are Elevated in Patients with Detrusor Overactivity and Decreased in Responders to Detrusor Botulinum Toxin-A Injection 
Achieving the Total Approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management  Michael O’Leary  European Urology Supplements 
Contemporary Management of the Painful Bladder: A Systematic Review
EAU Guidelines on Chronic Pelvic Pain
Prostate Cancer: Highlights from 2006
Management of Acute and Chronic Retention in Men
Volume 52, Issue 2, Pages (August 2007)
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Hormone Therapy for Prostate Cancer: Exploring Current Controversies
Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?
Rowland Illing  European Urology Supplements 
Martin C. Michel  European Urology Supplements 
Volume 63, Issue 1, Pages (January 2013)
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Back to the Future: Introduction and Conclusions
Sexual Dysfunction and Lower Urinary Tract Symptoms (LUTS) Associated with Benign Prostatic Hyperplasia (BPH)  Raymond C. Rosen, Francois Giuliano, Culley.
What is New in Hormone Therapy for Prostate Cancer in 2007?
Long-Term Management of Overactive Bladder with Antimuscarinic Agents
Impact of Nocturia on Sleep and Energy
Rowland Illing  European Urology Supplements 
Treatment of Symptomatic Benign Prostatic Hyperplasia: Current and Future Clinical Practice in Europe – What is Really Happening?  Bob Djavan  European.
Counselling the Prostate Cancer Patient
Laurent Boccon-Gibod  European Urology Supplements 
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
Glycosaminoglycan Therapy for Bladder Diseases: Emerging New Treatments  Pier Francesco Bassi, Elisabetta Costantini, Steve Foley, Stefano Palea  European.
Richard C. Harkaway  European Urology Supplements 
Tim Schneider  European Urology Supplements 
Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy  Bertrand Tombal, Richard Berges  European Urology.
Transurethral Resection of the Prostate
The Importance of Testosterone Control in Prostate Cancer
Antonio Alcaraz, Pierre Teillac  European Urology Supplements 
Jacques Irani  European Urology Supplements 
Optimal Testosterone Control and Eligard®
Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice  Claus Roehrborn  European Urology.
Volume 54, Issue 6, Pages (December 2008)
Kidney Cancer: Highlights from 2006
When to Treat the Prostate, the Bladder, or Both?
Therapeutic Use of Botulinum Toxin Type A in Treating Neck and Upper-Back Pain of Myofascial Origin: A Pilot Study  Henry L. Lew, MD, PhD, Eun Ha Lee,
Bladder Cancer: Highlights from 2006
Pharmacotherapy in Stress and Mixed Incontinence
Christian Stief  European Urology Supplements 
New Trends in Managing the Prostate Cancer Patient
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
Emmanuel Chartier-Kastler, Kate Davidson  European Urology Supplements 
A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study  John Fitzpatrick  European.
Martin Michel, Jean de la Rosette  European Urology Supplements 
Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer  P. Mongiat-Artus, P. Teillac 
How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?  Vincenzo Mirone 
Improving Flexibility and Quality of Life for Your Patients: A Must?
Profile of Silodosin European Urology Supplements
Stone Disease European Urology Supplements
Volume 52, Issue 6, Pages (December 2007)
New Concepts in Epidemiology of Lower Urinary Tract Symptoms in Men
LUTS and Sexual Dysfunction: Implications for Management of BPH
Prognostic Factors in Non–Muscle-Invasive Bladder Tumors
Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer  Sten Holmäng  European Urology.
Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma  Jan Roigas  European Urology Supplements  Volume.
Counselling of the Prostate Cancer Patient as a Whole Person
Joaquim Bellmunt  European Urology Supplements 
Economic and Social Impact of OAB
Emmanuel Chartier-Kastler, Andrea Tubaro  European Urology Supplements 
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Integrating Patient Risk Profiles in the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) in Clinical Practice 
New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer  Noel W. Clarke  European Urology Supplements 
Volume 54, Issue 1, Pages (July 2008)
Michael Marberger  European Urology Supplements 
Vassilios Tzortzis, Stavros Gravas, Jean J.M.C.H. de la Rosette 
Presentation transcript:

Functional Bladder Problems Emmanuel Chartier-Kastler  European Urology Supplements  Volume 6, Issue 12, Pages 710-716 (July 2007) DOI: 10.1016/j.eursup.2007.03.017 Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 1 The α1-adrenoceptor antagonist tamsulosin significantly reduced bladder wall hypertrophy in obstructed patients. Bladder wall hypertrophy was evaluated by ultrasound-estimated bladder weight (UEBW) [11]. NS=not significant. European Urology Supplements 2007 6, 710-716DOI: (10.1016/j.eursup.2007.03.017) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 2 Results from interactive voting on a representative case indicate that an urodynamic study is the preferred tool for diagnostic evaluation. Surprisingly, watchful waiting and cystoscopy are still frequently chosen. Only a minority of the participants chose urethrocystography as a diagnostic tool. European Urology Supplements 2007 6, 710-716DOI: (10.1016/j.eursup.2007.03.017) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 3 Results from interactive voting indicate that about half of the participants chose a transurethral resection of the prostate (TURP) as treatment option for a patient with bladder outlet obstruction, whereas a prostatic stent was a less favoured option. European Urology Supplements 2007 6, 710-716DOI: (10.1016/j.eursup.2007.03.017) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 4 Botulinum toxin A (BTX-A) injections significantly decreased daytime and nighttime urinary frequency as well as the Visual Analog Scale (VAS) score for bladder pain at 1- and 3-mo follow-up [18]. European Urology Supplements 2007 6, 710-716DOI: (10.1016/j.eursup.2007.03.017) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 5 Cyclosporine A significantly decreased 24-h micturition frequency compared with pentosan polysulfate sodium (PPS) in patients with interstitial cystitis (IC) [19]. European Urology Supplements 2007 6, 710-716DOI: (10.1016/j.eursup.2007.03.017) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 6 Results from interactive voting indicate that approximately an equal amount of participants chose between a urodynamic study and cystoscopy under general anaesthesia, and bladder biopsies as the tool for diagnostic evaluation of a patient with painful bladder syndrome/interstitial cystitis (PBS/IC). One of five delegates opted for the voiding diary. European Urology Supplements 2007 6, 710-716DOI: (10.1016/j.eursup.2007.03.017) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 7 Results from interactive voting on a representative case indicate that medical treatment, bladder hydrodistension, and bladder instillations are the preferred treatment options, whereas pelvic floor rehabilitation and surgery are less chosen therapies. European Urology Supplements 2007 6, 710-716DOI: (10.1016/j.eursup.2007.03.017) Copyright © 2007 European Association of Urology Terms and Conditions